Liu Hengrui, Li Yixue
Tianjin Yinuo Biomedical Co., Ltd., Tianjin, China.
Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Cancer Biomark. 2022;35(4):439-450. doi: 10.3233/CBM-220143.
It is of great clinical significance to discover novel biomarkers for neck squamous cell carcinoma (HNSCC) treatments. We discovered a potential cancer-related gene, Cornichon Family AMPA Receptor Auxiliary Protein 4 (CNIH4), that can be a biomarker for HNSCC.
We access multiple open databases and analyzed bulk mRNA-sequencing, protein staining, and single-cell mRNA-sequencing data of HNSCC and investigated the diagnostic and prognostic value of CNIH4 in HNSCC. The potential association between CNIH4 and the immune microenvironment of HNSCC was also estimated.
CNIH4 was significantly up-regulated in HNSCC compared with non-cancer tissues. Higher CNIH4 resulted in a shorter overall survival time and we further constructed a survival nomogram for clinical applications. 2012 and 421 genes were identified as positive and negative differentially expressed genes of CNIH4 in HNSCC respectively. These genes were mostly mapped to "Cell cycle", "DNA replicate", "Cytokine-cytokine receptor interaction" KEGG pathways. Functions associated with CNIH4 were "stemness", "cell cycle", and "DNA repair" in single-cell data. CNIH4 potentially affected immune cell infiltration levels and cancer immune therapy.
CNIH4 is a potential diagnostic and prognostic biomarker associated with cancer stemness and immunity in HNSCC.
发现用于头颈鳞状细胞癌(HNSCC)治疗的新型生物标志物具有重要的临床意义。我们发现了一个潜在的癌症相关基因,即科尼孔家族AMPA受体辅助蛋白4(CNIH4),它可能成为HNSCC的生物标志物。
我们访问了多个开放数据库,分析了HNSCC的批量mRNA测序、蛋白质染色和单细胞mRNA测序数据,并研究了CNIH4在HNSCC中的诊断和预后价值。还评估了CNIH4与HNSCC免疫微环境之间的潜在关联。
与非癌组织相比,CNIH4在HNSCC中显著上调。CNIH4水平越高,总生存时间越短,我们进一步构建了用于临床应用的生存列线图。分别鉴定出2012个和421个基因作为HNSCC中CNIH4的正向和负向差异表达基因。这些基因大多映射到“细胞周期”、“DNA复制”、“细胞因子-细胞因子受体相互作用”KEGG通路。在单细胞数据中,与CNIH4相关的功能是“干性”、“细胞周期”和“DNA修复”。CNIH4可能影响免疫细胞浸润水平和癌症免疫治疗。
CNIH4是一种与HNSCC癌症干性和免疫相关的潜在诊断和预后生物标志物。